Visit https://www.peervoice.com/XYZ860 to view the entire programme with slides. After completing “Kris V. Kowdley, MD - Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Novel Therapies”, participants will be able to: Describe the clinical presentation and biochemical abnormalities in patients with primary biliary cholangitis (PBC) and progressive familial intrahepatic cholestasis (PFIC); Utilize practical approaches, including evidence-based tools, to evaluate and predict response to therapy and facilitate treatment decision-making in patients with cholestatic liver disease; Appraise the data from trials and studies examining the safety and efficacy of therapies in PBC and PFIC; and Implement evidence-based treatment strategies to optimize clinical and patient-related outcomes in the management of PBC and PFIC.

Visit https://www.peervoice.com/XAD860 to view the entire programme with slides. After completing “Marla C. Dubinsky, MD / David T. Rubin, MD - TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?”, participants will be able to: Recall the evidence of the impact of tumor necrosis factor (TNF) inhibitors on endoscopic outcomes in patients with inflammatory bowel disease (IBD); Use clinical data to illustrate the potential benefits of early intervention with; TNF inhibitors in patients with IBD; Explain the importance of maintaining a steady, stable serum drug level during maintenance treatment of IBD with a TNF inhibitor; and Apply recommended approaches for effective and safe management of patients receiving TNF inhibitor-based maintenance therapy that optimizes both clinical and patient outcomes.

Visit https://www.peervoice.com/GWC860 to view the entire programme with slides. After completing “Philip James Tozer, MBBS, MD(Res), FRCS - Multidisciplinary Perspectives on Advanced Management of CPF in CD: Exploring the Who, When, and How for Stem Cell Therapy”, participants will be able to: Evaluate efficacy and safety outcomes for advanced therapies, including stem cell therapy, which guide their incorporation into treatment plans for patients with complex perianal fistulas (CPF) due to Crohn’s disease (CD); Identify the role of magnetic resonance imaging in the assessment of CPF and treatment response in patients with CD; and Propose multidisciplinary care plans for patients with CPF due to CD.

Visit https://www.peervoice.com/TKB860 to view the entire programme with slides. After completing “Andreas Kremer, MD, PhD, MHBA - Initiating the Conversation on Itch: Modelling Best Practices in Patient-Centred Care for Cholestatic Pruritus in PBC”, participants will be able to: Describe the impact of uncontrolled cholestatic pruritus on patient quality of life, mental health, and overall outcomes in primary biliary cholangitis (PBC); Summarise key patient counselling and education points related to cholestatic pruritus in PBC; and Incorporate effective communication and information-gathering strategies to improve evaluation of cholestatic pruritus in PBC.

Visit https://www.peervoice.com/KQF860 to view the entire programme with slides. After completing “Andreas Kremer, MD, PhD, MHBA - Incorporating the Investigation of Itch Into the Patient Care Process for PBC: Practical Steps, Tips, and Tools”, participants will be able to: Recognise the consequences of uncontrolled cholestatic pruritus on quality of life and outcomes in patients with primary biliary cholangitis (PBC); Demonstrate ability to use effective strategies when discussing and evaluating cholestatic pruritus in patients with PBC; and Evaluate both current and novel investigational strategies for management of cholestatic pruritus.

Visit https://www.peervoice.com/GSQ860 to view the entire programme with slides. After completing “David T. Rubin, MD, AGAF - What They Say and What They Think: Exploring Tools for Assessing Bowel Urgency in Patients with Ulcerative Colitis”, participants will be able to: Discuss latest evidence on bowel urgency in patients with ulcerative colitis (UC) and its influence on quality of life; Analyze current communication gaps between patients with UC and clinicians during clinic visits; and Recognize the benefits and limitations of current patient-reported outcomes tools.

Visit https://www.peervoice.com/CCV860 to view the entire programme with slides. After completing “Advanced Therapy for CPF in Crohn's: Evaluating the Evidence for Stem Cell Therapy and More”, participants will be able to: Summarise key findings from the literature on advanced treatment options for complex perianal fistula (CPF) in Crohn’s disease; Review the strengths and limitations of these data in the context of current practice for CPF; and Describe the impact of these data on clinical practice.